COVID Update: Masks are still required in health care settings, even if you’re fully vaccinated. Read our FAQs.

Combined Immunotherapy and Radiation Therapy for Non-Small Cell Lung Cancer

Trial ID:
IRB-21-7750
Michael P. Kosty, M.D.
This study will test the effectiveness of Durvalumab (IMFINZI) given during and after radiation treatment in patients with non-small cell lung cancer. Durvalumab is used as an immune-enhancing medication, that may block immune pathways for tumor growth.

Inclusion Criteria

Patients must:
  • Be 18 years of age or older
  • Have confirmed diagnosis of Non-small cell lung cancer (NSCLC), Clinical Stage I/II lymph-node negative (T1 to T3N0M0)
  • Be medically inoperable as determined by your physician or patient refusal of surgery
  • Plan to receive stereotactic body radiation therapy (SBRT)

Exclusion Criteria

Patients must not:
  • Have active or prior autoimmune or inflammatory disorders
  • Have history of another primary cancer
  • Have history of organ transplantation
  • Have active infection of Tuberculosis, Hepatitis B, Hepatitis C or HIV

Additional Info

  • All patients will receive standard of care stereotactic body radiation therapy (SBRT), and will be randomly selected to receive either Durvalumab or placebo via intravenous (IV) infusion. Study treatment and physician visits will take place at Scripps Clinic Torrey Pines (Geisel Pavilion) and occur once monthly for up to two years.
  • Search for NCT03833154 on www.clinicaltrials.gov for additional information.

Contact Info:

  • Clinical Research Services
  • CRSLeadership@scrippshealth.org